IL6 and chronic kidney disease: The recentphase II Reduction in Inflammation in Patients with Advanced Chronic RenalDisease Utilising Antibody Mediated IL-6 Inhibition (RESCUE) trial showed thatIL-6 inhibition with ziltivekimab successfully reduced IL-6 and hsCRP levels inpatients with stage 3–5 CKD (eGFR 10–60 mL/min/1.73 m2) [121].